Toggle light / dark theme

Top Nanotechnology Expert to Lead UVA’s NanoSTAR Institute

Evan A. Scott, PhD, comes to UVA from Northwestern University, where he has conducted groundbreaking research into the use of tiny nanostructures to battle heart disease, cancer, glaucoma and more. Scott’s nanostructures, far too small for the eye to see, allow for the precise delivery of drugs and other therapeutics to specific inflammatory cells to benefit the body’s immune response. His research provides important answers about the fundamental processes responsible for diseases and paves the way for high-tech treatments using cleverly designed, and mind-blowingly miniscule, synthetic materials.

“We are excited to welcome Dr. Scott to head up nanoSTAR at this critical turning point in nanotechnology research at the University of Virginia,” said Melina R. Kibbe, MD, dean of the School of Medicine. “Nanotechnology has vast untapped potential to benefit patients everywhere. It is a long-standing strength for UVA and will be a foundational pillar of the Paul and Diane Manning Institute of Biotechnology.”

The Manning Institute, under construction at Fontaine Research Park, will tackle some of the greatest challenges in medicine by focusing on cutting-edge areas of research such as nanotechnology, targeted drug delivery, cellular therapies and gene therapy. NanoSTAR, with Scott at the helm, will play a key role in that nanotechnology research, and Scott will work to foster collaborations across Grounds, including among the School of Medicine, School of Engineering and Applied Science, School of Data Science and the College of Arts and Sciences, among others.

Researchers set new standards for nanoparticles, helping patients with MS, ALS, Parkinson’s disease

Is it possible for nanoparticles to go through the digestive system and deliver medicine directly to the brain tissue? Researchers from Michigan State University say yes, and their latest findings are expected to benefit patients with neurodegenerative disorders like multiple sclerosis, or MS; amyotrophic lateral sclerosis, or ALS; and Parkinson’s disease, or PD.

Powerful New Tool Ushers In New Era of Quantum Materials Research

Professor Fabio Boschini (above) and his colleagues are at the forefront of research in quantum materials, employing time-and angle-resolved photoemission spectroscopy (TR-ARPES) to drive technological breakthroughs in industries like mining, energy, and healthcare. Their recent work, demonstrates how TR-ARPES enhances the understanding and manipulation of material properties through light-matter interaction. Credit: Fabio Boschini (INRS)

Research into quantum materials is leading to revolutionary breakthroughs and is set to propel technological progress that will transform industries such as mining, energy, transportation, and medical technology.

A technique called time-and angle-resolved photoemission spectroscopy (TR-ARPES) has emerged as a powerful tool, allowing researchers to explore the equilibrium and dynamical properties of quantum materials via light-matter interaction.

Understanding heart regeneration and the potential for human applications

“My hunch is the ancestor of all animals could regenerate its heart after an injury, and then that’s been repeatedly lost in different types of animals,” said Dr. James Gagnon. “I would like to understand why. Why would you lose this great feature that allows you to regenerate your heart after an injury?”


Can the heart physiology of zebrafish help treat human heart conditions? This is what a recent study published in Biology Open hopes to address as a team of researchers from the University of Utah compared the fish species of zebrafish and medaka since the former possesses heart regeneration capabilities while the latter does not. This study holds the potential to help researchers better understand the physiological processes responsible for fixing heart tissue after damage from a heart attack or other ailment that could lead to more advanced human treatments.

“We thought by comparing these two fish that have similar heart morphology and live in similar habitats, we could have a better chance of actually finding what the main differences are,” said Dr. Clayton Carey, a postdoctoral fellow at the University of Utah and lead author of the study.

For the study, the researchers injured the heart of each fish species that mirrored human heart attacks then removed the hearts after between 3 to 14 days after the procedure to examine how each was repaired since the injury. While 95 percent of the fish initially survived the procedure, they perished shortly afterwards. The team focused on analyzing immune cell behavior with the team noting that zebrafish possess certain types of muscle cells that weren’t present in medaka. In the end, the researchers concluded that evolutionary divergence was the likely reason why zebrafish possess heart regeneration capabilities whereas medaka do not.

CBN: A Potential Neuroprotective Compound from Cannabis

Cannabinol (CBN) is a chemical found in cannabis that exhibits milder psychoactive properties than most cannabis chemicals, though research pertaining to its medical applications remains limited. Now, a team of researchers led by The Salk Institute for Biological Studies have published a study in Redox Biology that addresses the potential for CBN to serve as a method for neurological disorders, including traumatic brain injuries, Parkinson’s disease, and Alzheimer’s disease.

For the study, the researchers produced four CBN analogs that exhibited greater neuroprotective capabilities compared to the traditional CBN molecule and tested them on Drosophila fruit flies. In the end, the researchers discovered these CBN analogs possessed neuroprotective capabilities that surpassed traditional CBN molecules, including the treating of traumatic brain injuries. While not tested during this study, these CBN analogs could be used to also treat a myriad of neurological disorders, including Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease.

“Our findings help demonstrate the therapeutic potential of CBN, as well as the scientific opportunity we have to replicate and refine its drug-like properties,” said Dr. Pamela Maher, who is a research professor in the Cellular Neurobiology Laboratory at Salk and a co-author on the study. “Could we one day give this CBN analog to football players the day before a big game, or to car accident survivors as they arrive in the hospital? We’re excited to see how effective these compounds might be in protecting the brain from further damage.”

A common pathway in the brain that enables addictive drugs to hijack natural reward processing identified

Mount Sinai researchers, in collaboration with scientists at The Rockefeller University, have uncovered a mechanism in the brain that allows cocaine and morphine to take over natural reward processing systems. Published online in Science on April 18, these findings shed new light on the neural underpinnings of drug addiction and could offer new mechanistic insights to inform basic research, clinical practice, and potential therapeutic solutions.

Novel Schizophrenia Insights from Brain Organoids and Genes

Although schizophrenia can be a very complex illness some new studies show that some major genetic factors could be the cause and then cured much easier through gene therapy.


Summary: Researchers leveraged cutting-edge technology to gain insights into schizophrenia’s neurodevelopmental origins. The researchers grew brain organoids from patients’ skin cells, finding persistent axonal disruptions in those with schizophrenia.

In another study, researchers zeroed in on a schizophrenia risk gene, CYFIP1, revealing its potential role in brain immune cells called microglia and their influence on synaptic pruning – a crucial process for brain health.